PBYI Puma Biotechnology Inc
$10.92▲ +0.65%
Healthcare
Other
After hours
$10.92▲ +0.00%
Oct 27, 4:27 PM ET
Volume 308.8K
Avg Volume (10D) 384.8K
Key Metrics & Fundamentals
Market Cap
$563.69M
P/E Ratio
21.4
Div Yield
0.00%
52W Range
4.58 - 11.50
% vs 50 MA
12.12%
% vs 200 MA
39.10%
RSI-14
61.6
MACD Histogram
+0.0600
Beta (1Y vs SPY)
0.53
Free Cash Flow
$1.62M
Gross Rev
$56.50M
Gross Profit
$44.03M
EBITDA
$10.94M
COGS
$12.48M
Operating Exp
$36.44M
Operating Income
$7.59M
EBIT
$7.59M
Pretax Income
$8.25M
Net Income
$8.19M
EPS (Diluted)
0.16
Price & Volume History
Loading chart…
Recent News
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
Business Wire · Oct 22, 2026 4:11 PM ET
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
Zacks · Oct 20, 2026 8:40 AM ET
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
Zacks · Oct 19, 2026 8:00 AM ET
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Zacks · Oct 16, 2026 8:45 AM ET
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Oct 5, 2026 5:00 PM ET
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Zacks · Sep 18, 2026 10:48 AM ET
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Business Wire · Sep 17, 2026 4:07 PM ET
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
Business Wire · Sep 9, 2026 4:11 PM ET
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
Zacks · Sep 9, 2026 11:30 AM ET
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Sep 3, 2026 5:00 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See PBYI's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.